Table 7.
Quantitative results of apoptotic effects of A549, MCF7 and Caco-2 cells, determined by Annexin V/FITC assay, for cells treated with IC50 concentration of Cisplatin and Pt(TSC)Cl complex. Cells with no treatment considered as control group.
| A549 | MCF-7 | Caco-2 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Control | Cis | Pt(TSC)Cl complex |
Control | Cis | Pt(TSC)Cl complex |
Control | Cis | Pt(TSC)Cl complex |
|
|
Viable (PI-/FITC-) |
98.1 | 82.9 | 85.2 | 98.6 | 77.9 | 67.3 | 99.2 | 75.9 | 5.58 |
|
Early apoptosis (PI-/FITC+) |
0 | 7.50 | 3.74 | 1.35 | 8.48 | 6.47 | 0.39 | 14.9 | 37.3 |
|
Late apoptosis (PI+/FITC+) |
0.033 | 7.83 | 7.12 | 0.087 | 10.4 | 23.8 | 0.25 | 6.27 | 52.4 |
|
Necrosis (PI+/FITC-) |
1.87 | 1.73 | 3.9 | 0 | 3.24 | 2.38 | 0.14 | 2.91 | 4.79 |
*Cis: Cisplatin, A549: Human lung cancer cells, Caco-2: Human colon cancer cells, MCF-7 Human breast cancer cells.